TABLE 1.
Demographic and pulmonary function characteristics of participants
| PLWH (N=380) | HIV-participants (N=147) | P value | Adjusted P value* | |
|---|---|---|---|---|
| Age (year), median (IQR) | 51 (43–56) | 51 (42–57) | 0.7 | |
| Female, n (%) | 124 (33) | 68 (47) | 0.004 | |
| Race, n (%) | 0.43 | |||
| Caucasian | 168 (44) | 74 (50) | ||
| African American | 195 (51) | 68 (46) | ||
| Other | 17 (5) | 5 (3) | ||
| Smoking status, n (%) | 0.14 | |||
| Never | 115 (30) | 57 (39) | ||
| Former | 96 (25) | 36 (25) | ||
| Current | 169 (45) | 54 (37) | ||
| Total Pack-years, median (IQR) | 8 (0–22) | 5 (0–16) | 0.043 | |
| CD4+ T lymphocyte count (cells/μl), median (IQR) | 615 (404–853) | NA | NA | |
| Plasma HIV RNA <40 copies/ml, n (%) | 252 (73) ^ | NA | NA | |
| Current ART use, n (%) | 352 (93%) | NA | NA | |
| ART duration (year), median (IQR) | 5.6 (4.5–6.6) | NA | NA | |
| Post FEV1%, median (IQR) | 93 (80–106) | 94 (82–106) | 0.5 | >0.9 |
| Post FVC%, median (IQR) | 93 (80–103) | 92 (83–104) | 0.6 | 0.9 |
| Post FEV1/FVC, median (IQR) | 81 (75–84) | 81 (76–84) | 0.9 | 0.7 |
| DLco%, median (IQR) | 79 (68–90) | 86 (77–95) | 0.0001 | 0.002 |
IQR: interquartile range; ART: antiretroviral therapy; Post FEV1%: percent predicted post-bronchodilator (BD) forced expiratory volume in 1 second; Post FVC%: percent predicted post-BD forced vital capacity; DLco%: percent single breath diffusing capacity for carbon monoxide.
*
Adjusted for age, gender, pack- years.
^
N=344.